DIVIS LABORATORIES Financial Statement Analysis
|
||
The Revenues of DIVIS LABORATORIES have increased by 28.56% YoY .
The Earnings Per Share (EPS) of DIVIS LABORATORIES has decreased by -38.41 % YoY. |
REVENUES |
OPERATING MARGIN |
PROFIT AFTER TAX |
EPS |
ROCE |
DIVIS LABORATORIES Last 5 Annual Financial Results
[BOM: 532488|NSE : DIVISLAB]
Consolidated | Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 |
---|---|---|---|---|---|
Revenues | ₹8,960 Cr | ₹6,969 Cr | ₹5,394 Cr | ₹4,946 Cr | ₹3,891 Cr |
Expenses | ₹5,079 Cr | ₹4,108 Cr | ₹3,571 Cr | ₹3,073 Cr | ₹2,629 Cr |
Operating Profit (Excl OI) | ₹3,881 Cr | ₹2,861 Cr | ₹1,823 Cr | ₹1,873 Cr | ₹1,263 Cr |
Other Income | ₹116 Cr | ₹63 Cr | ₹190 Cr | ₹156 Cr | ₹113 Cr |
Interest | ₹2.00 Cr | ₹2.10 Cr | ₹7.14 Cr | ₹4.68 Cr | ₹2.37 Cr |
Depreciation | ₹312 Cr | ₹256 Cr | ₹186 Cr | ₹169 Cr | ₹142 Cr |
Profit Before Tax | ₹3,684 Cr | ₹2,666 Cr | ₹1,819 Cr | ₹1,855 Cr | ₹1,231 Cr |
Profit After Tax | ₹2,960 Cr | ₹1,984 Cr | ₹1,377 Cr | ₹1,353 Cr | ₹877 Cr |
Consolidated Net Profit | ₹2,960 Cr | ₹1,984 Cr | ₹1,377 Cr | ₹1,353 Cr | ₹877 Cr |
Earnings Per Share (Rs) | ₹68.69 | ₹111.53 | ₹74.75 | ₹51.86 | ₹50.96 |
PAT Margin (%) | 23.32 | 32.94 | 28.38 | 25.23 | 27.15 |
ROE(%) | 14.89 | 28.16 | 23.90 | 19.30 | 21.00 |
ROCE(%) | 19.36 | 35.06 | 32.07 | 25.36 | 28.50 |
Total Debt/Equity(x) | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 |
Key Financials |
||
Market Cap | : | ₹ 104,312.3 Cr |
Revenue (TTM) | : | ₹ 7,492.8 Cr |
Net Profit(TTM) | : | ₹ 1,383.0 Cr |
EPS (TTM) | : | ₹ 52.1 |
P/E (TTM) | : | 75.4 |
Industry Peers & Returns | 1W | 1M | 1Y |
DIVIS LABORATORIES | -0.9% | 5% | 19.2% |
SUN PHARMACEUTICAL INDUSTRIES | 0.2% | -6.1% | 55.7% |
CIPLA | -2.5% | -5.1% | 48.6% |
DR REDDYS LABORATORIES | -3.7% | -1.4% | 26% |
ZYDUS LIFESCIENCES | 1.8% | 2.2% | 88.6% |
MANKIND PHARMA | -6.6% | -6.6% | NA |
TORRENT PHARMACEUTICALS | -3.2% | 1.8% | 57.6% |
LUPIN | -1.9% | 1.8% | 126.8% |
AUROBINDO PHARMA | -1.6% | 1.1% | 83.7% |
DIVIS LABORATORIES Revenues
[BOM: 532488|NSE : DIVISLAB]
Y-o-Y | 28.56 % |
5 Yr CAGR | 23.18 % |
Years | Revenues | % Change | |
---|---|---|---|
Mar2023 | ₹8,960 Cr | 28.56 | |
Mar2022 | ₹6,969 Cr | 29.20 | |
Mar2021 | ₹5,394 Cr | 9.06 | |
Mar2020 | ₹4,946 Cr | 27.10 | |
Mar2019 | ₹3,891 Cr | - |
DIVIS LABORATORIES Operating Profit
[BOM: 532488|NSE : DIVISLAB]
Y-o-Y | 35.65 % |
5 Yr CAGR | 32.41 % |
Years | Operating Profit | % Change | |
---|---|---|---|
Mar2023 | ₹3,881 Cr | 35.65 | |
Mar2022 | ₹2,861 Cr | 56.92 | |
Mar2021 | ₹1,823 Cr | -2.66 | |
Mar2020 | ₹1,873 Cr | 48.33 | |
Mar2019 | ₹1,263 Cr | - |
Operating Margins | |
---|---|
Y-o-Y | 5.53 % |
5 Yr CAGR | 7.49 % |
Years | Operating Margin% | % Change | |
---|---|---|---|
Mar2023 | 43.32% | 5.53 | |
Mar2022 | 41.05% | 21.45 | |
Mar2021 | 33.8% | -10.75 | |
Mar2020 | 37.87% | 16.70 | |
Mar2019 | 32.45% | - |
DIVIS LABORATORIES Profit After Tax
[BOM: 532488|NSE : DIVISLAB]
Y-o-Y | 49.19 % |
5 Yr CAGR | 35.55 % |
Years | Profit After Tax | % Change | |
---|---|---|---|
Mar2023 | ₹2,960 Cr | 49.19 | |
Mar2022 | ₹1,984 Cr | 44.15 | |
Mar2021 | ₹1,377 Cr | 1.76 | |
Mar2020 | ₹1,353 Cr | 54.24 | |
Mar2019 | ₹877 Cr | - |
PAT Margins | |
---|---|
Y-o-Y | -29.20 % |
5 Yr CAGR | -3.73 % |
Years | PAT Margin(%) | % Change | |
---|---|---|---|
Mar2023 | 23.32 % | -29.20 | |
Mar2022 | 32.94 % | 16.07 | |
Mar2021 | 28.38 % | 12.49 | |
Mar2020 | 25.23 % | -7.07 | |
Mar2019 | 27.15 % | - |
DIVIS LABORATORIES Earnings Per Share (EPS)
[BOM: 532488|NSE : DIVISLAB]
Y-o-Y | -38.41 % |
5 Yr CAGR | 7.75 % |
Years | EPS | % Change | |
---|---|---|---|
Mar2023 | ₹69 | -38.41 | |
Mar2022 | ₹112 | 49.20 | |
Mar2021 | ₹75 | 44.14 | |
Mar2020 | ₹52 | 1.77 | |
Mar2019 | ₹51 | - |
DIVIS LABORATORIES Return on Capital Employed (ROCE)
[BOM: 532488|NSE : DIVISLAB]
Y-o-Y | -44.78 % |
5 Yr CAGR | -9.21 % |
Years | ROCE | % Change | |
---|---|---|---|
Mar2023 | 19.36% | -44.78 | |
Mar2022 | 35.06% | 9.32 | |
Mar2021 | 32.07% | 26.46 | |
Mar2020 | 25.36% | -11.02 | |
Mar2019 | 28.5% | - |
DIVIS LABORATORIES Share Price vs Sensex
Current Share Price | : | ₹3,928.9 |
Current MarketCap | : | ₹ 104,312.3 Cr |
Updated EOD on | : | May 08,2024 |
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
DIVIS LABORATORIES | -0.9% |
5% |
19.2% |
SENSEX | -1.4% |
-0.6% |
20.1% |
DIVIS LABORATORIES related INDICES
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
S&P BSE DIVIDEND STABILITY | -0.2% | 1% | 53.7% |
MFG | -0.7% | -0.1% | 39.5% |
S&P BSE HEALTHCARE | -1% | -1.1% | 52.2% |
S&P BSE CARBONEX | -1.1% | 0.1% | 27.7% |
S&P BSE 100 | -1.1% | 0.1% | 27.9% |
NSE Indices | 1W | 1M | 1Y |
---|---|---|---|
NIFTY GROWTH SECTOR 15 | 1.2% | 11.6% | 9.1% |
NSE QUALITY 30 | 1% | 1.5% | 31.9% |
NIFTY200 QUALITY30 | 0.8% | 0.3% | 29% |
NIFTY 100 EQUAL WEIGHT | -0.6% | 0.9% | 47.8% |
NIFTY PHARMA | -0.6% | -1.6% | 49.8% |
You may also like the below Video Courses
FAQ about DIVIS LABORATORIES Financials
How the annual revenues of DIVIS LABORATORIES have changed ?
The Revenues of DIVIS LABORATORIES have increased by 28.56% YoY .
How the Earnings per Share (EPS) of DIVIS LABORATORIES have changed?
The Earnings Per Share (EPS) of DIVIS LABORATORIES has decreased by -38.41 % YoY .
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs